Summary Genticel SA (Genticel), formerly BT Pharma, is a biopharmaceutical company that develops therapeutic vaccines for women infected by the human papillomavirus. The company provides pipeline products including ProCervix, a bivalent HPV therapeutic vaccine candidate and multivalent candidate vaccines for patients infected with HPV. It offers technologies such as CyaA vector platform and Vaxiclase for developing products. Genticel also provides clinical trials services. The company’s ProCe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.